When.com Web Search

Search results

1. Results From The WOW.Com Content Network

2. Olanzapine - Wikipedia

   en.wikipedia.org/wiki/Olanzapine

   Olanzapine occupancy at 5-HT 2A receptor are high at all doses (5 mg to 20 mg). It is reported that 5 mg dose of olanzapine produced a mean occupancy of 85% at 5 mg, 88% at 10 mg, and 93% at 20 mg dose . [95] Olanzapine had the highest affinity of any second-generation antipsychotic towards the P-glycoprotein in one in vitro study. [96]

3. Olanzapine/fluoxetine - Wikipedia

   en.wikipedia.org/wiki/Olanzapine/fluoxetine

   Olanzapine/fluoxetine was approved by the U.S. Food and Drug Administration (FDA) to treat the depressive episodes of bipolar I disorder in 2003. [1] In 2009, it was granted approval for the treatment of treatment-resistant depression.

4. List of antidepressants - Wikipedia

   en.wikipedia.org/wiki/List_of_antidepressants

   This is a complete list of clinically approved prescription antidepressants throughout the world, as well as clinically approved prescription drugs used to augment antidepressants or mood stabilizers, by pharmacological and/or structural classification.

5. New type of non-opioid pain medication approved by FDA - AOL

   www.aol.com/type-non-opioid-pain-medication...

   The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) oral tablets on Thursday as a first-in-class non-opioid analgesic to treat acute pain in adults.

6. Olanzapine/samidorphan - Wikipedia

   en.wikipedia.org/wiki/Olanzapine/samidorphan

   Olanzapine/samidorphan, sold under the brand name Lybalvi, is a fixed-dose combination medication for the treatment of schizophrenia and bipolar I disorder. [1] It contains olanzapine , an atypical antipsychotic , and samidorphan , an opioid antagonist .

7. FDA approves oral medication treating postpartum depression - AOL

   www.aol.com/lifestyle/fda-approves-oral...

   Aug. 19—A new drug treating postpartum depression was approved earlier this month by the Food and Drug Administration — possibly filling a gap in care, depending on the drug's accessibility to ...